Professor Anton Berns
Professor Anton Berns is Director of Research at the Netherlands Cancer Institute.

"The relationship with CRT has helped us enormously in evaluating and securing our intellectual property. In addition, CRT’s worldwide contacts with the biotechnology and pharmaceutical industry make it possible to exploit our discoveries in such a way that it will benefit cancer patients. We are looking forward to working with them in the years to come."

Dr Rene Bernards
Dr Bernards is Head of the Division of Molecular Carcinogenesis at the Netherlands Cancer Institute, Amsterdam.

"The key thing at this point is the patent position for RNAi. CRT is working hard to make agreements with people holding other positions, which is what we need now. They’re driving the process. I don’t have the time to even think about it. That’s exactly why you want a technology transfer office."

"The people at CRT know what they are talking about.They really know the business. Our experience has been very positive."

Professor Herbie Newell
Professor Newell holds the Chair of Cancer Therapeutics at the University of Newcastle-upon-Tyne and co-directs the Cancer Research UK Developmental Therapeutics Programme.

"If you want your research to lead to a better treatment or a better diagnostic, then I would not be able to identify a better qualified group of people to talk to...",

"...there is obviously no better way for industry to find out about what’s going on in cancer research than to talk to CRT about what might be available commercially."

Professor Steve Jackson
Steve Jackson is Professor of Biology at the University of Cambridge and Deputy Chairman of the Wellcome Trust/Cancer Research UK Institute. He is also Chief Scientific Officer at KuDOS Pharmaceuticals Ltd.

"I would say that CRT was very far sighted to realise that a company like KuDOS, rather than a large pharmaceutical company, was the best vehicle to maximise the clinical promise of PaTrin-2. It is clear that CRT licensed it to us for commercial reasons, because KuDOS has the right skill set to get the most out of PaTrin-2 and deliver its full clinical potential."

"Just the fact that you are linked to CRT, and therefore to Cancer Research UK, gives you a pedigree, making it easier to approach collaborators, companies or investors.We have established a very productive and symbiotic relationship with CRT, which I hope that we can maintain."